Elan Says It Has Cured Tysabri Contract Breach

Law360, New York (September 14, 2009, 7:50 PM EDT) -- Elan Corp. PLC claims to have cured a breach of a contract with Biogen Idec Inc., which would allow an $885 million Alzheimer's drug deal with Johnson & Johnson to go forward.

Elan announced Monday that the “unintended” breach had been cured by amending a contract with Johnson & Johnson to exclude a section related to Tysabri, a multiple sclerosis drug jointly marketed by Elan and Biogen.

A spokeswoman for Biogen declined to comment on her company’s position on the purported contract cure.

The July 2...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.